Background TMC278, a next-generation NNRTI, has demonstrated in-vitro activity against wild-type and NNRTI-resistant isolates 1 48-week results from an.
Background
Www.aids2014.org The HDAC inhibitor romidepsin is safe and effectively reverses HIV-1 latency in vivo as measured by standard clinical assays Ole Schmeltz.
Can dose-optimization trials be conducted ethically in low-income countries? Dr Andrew Hill World AIDS Conference, Melbourne, Australia July 2014 [TUWS1104]
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER NNRTI Resistance David H. Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of.
![Can dose-optimization trials be conducted ethically in low-income countries? Dr Andrew Hill World AIDS Conference, Melbourne, Australia July 2014 [TUWS1104]](https://static.fdocuments.us/doc/330x215/56649d705503460f94a52ae7/can-dose-optimization-trials-be-conducted-ethically-in-low-income-countries.jpg)
